神经外科医师大会对功能性垂体腺瘤患者放射治疗的系统评价和循证指南。

IF 3.9 2区 医学 Q1 CLINICAL NEUROLOGY
Sheryl Green, Eric J Lehrer, Christopher P Cifarelli, Pablo F Recinos, Jason P Sheehan, Mateo Ziu, D Ryan Ormond, Isabelle M Germano
{"title":"神经外科医师大会对功能性垂体腺瘤患者放射治疗的系统评价和循证指南。","authors":"Sheryl Green, Eric J Lehrer, Christopher P Cifarelli, Pablo F Recinos, Jason P Sheehan, Mateo Ziu, D Ryan Ormond, Isabelle M Germano","doi":"10.1227/neu.0000000000003582","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients with functioning pituitary adenomas (FPA) require a multidisciplinary team-based approach to select best medical, surgical, and radiation treatments, including stereotactic radiosurgery (SRS).</p><p><strong>Objective: </strong>The aim of this study was to provide evidence-based recommendations on the use of SRS for adult patients with FPA.</p><p><strong>Methods: </strong>PubMed and Embase were searched from data base inception to June 8, 2021. Full-text articles were then screened using published exclusion/inclusion criteria. Evidence tables were developing based on data extraction from the full-text reviews, and evidence-based recommendations were finalized.</p><p><strong>Results: </strong>Of the total 1842 abstracts pertinent to this topic, 343 full articles met eligibility. Of these, 21 met entry criteria and were included in the evidence tables. The provided Class III evidence supported 2 Level III recommendations: 1. SRS, hypofractionated SRS, fractionated (>5 fractions) radiotherapy, and conventional radiation therapy provide excellent radiographic control with variable hormonal reduction and endocrine remission rates. For SRS and fractionated radiotherapy hormonal reduction may continue for up to 10 years after treatment. 2. Clinicians may continue to administer endocrine suppressive medical treatment before SRS as this may not affect radiographic control.</p><p><strong>Conclusion: </strong>This systematic review provides evidence-based recommendations to guide providers caring for adult patients with FPA when making decisions pertinent to radiosurgery. The CNS Guidelines Committee will continue to pursue timely updates to further improve the care of patients with this diagnosis.</p>","PeriodicalId":19276,"journal":{"name":"Neurosurgery","volume":"97 3S","pages":"S36-S43"},"PeriodicalIF":3.9000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines for the Role of Radiosurgery for Patients With Functioning Pituitary Adenomas.\",\"authors\":\"Sheryl Green, Eric J Lehrer, Christopher P Cifarelli, Pablo F Recinos, Jason P Sheehan, Mateo Ziu, D Ryan Ormond, Isabelle M Germano\",\"doi\":\"10.1227/neu.0000000000003582\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Patients with functioning pituitary adenomas (FPA) require a multidisciplinary team-based approach to select best medical, surgical, and radiation treatments, including stereotactic radiosurgery (SRS).</p><p><strong>Objective: </strong>The aim of this study was to provide evidence-based recommendations on the use of SRS for adult patients with FPA.</p><p><strong>Methods: </strong>PubMed and Embase were searched from data base inception to June 8, 2021. Full-text articles were then screened using published exclusion/inclusion criteria. Evidence tables were developing based on data extraction from the full-text reviews, and evidence-based recommendations were finalized.</p><p><strong>Results: </strong>Of the total 1842 abstracts pertinent to this topic, 343 full articles met eligibility. Of these, 21 met entry criteria and were included in the evidence tables. The provided Class III evidence supported 2 Level III recommendations: 1. SRS, hypofractionated SRS, fractionated (>5 fractions) radiotherapy, and conventional radiation therapy provide excellent radiographic control with variable hormonal reduction and endocrine remission rates. For SRS and fractionated radiotherapy hormonal reduction may continue for up to 10 years after treatment. 2. Clinicians may continue to administer endocrine suppressive medical treatment before SRS as this may not affect radiographic control.</p><p><strong>Conclusion: </strong>This systematic review provides evidence-based recommendations to guide providers caring for adult patients with FPA when making decisions pertinent to radiosurgery. The CNS Guidelines Committee will continue to pursue timely updates to further improve the care of patients with this diagnosis.</p>\",\"PeriodicalId\":19276,\"journal\":{\"name\":\"Neurosurgery\",\"volume\":\"97 3S\",\"pages\":\"S36-S43\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-08-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurosurgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1227/neu.0000000000003582\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurosurgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1227/neu.0000000000003582","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:功能性垂体腺瘤(FPA)患者需要以多学科团队为基础的方法来选择最佳的医学、外科和放射治疗,包括立体定向放射外科(SRS)。目的:本研究的目的是为成年FPA患者使用SRS提供循证建议。方法:检索PubMed和Embase数据库自建库至2021年6月8日。然后使用已发表的排除/纳入标准筛选全文文章。根据从全文综述中提取的数据,正在编制证据表,并最终确定了基于证据的建议。结果:在与该主题相关的1842篇摘要中,有343篇完整文章符合资格。其中21例符合入组标准,被纳入证据表。提供的III级证据支持2项III级建议:SRS、低分割SRS、分割(bbb50分)放疗和常规放射治疗提供了出色的放射学控制,具有不同的激素减少和内分泌缓解率。对于SRS和分割放疗,激素减少可能在治疗后持续长达10年。2. 临床医生可以在SRS之前继续给予内分泌抑制药物治疗,因为这可能不会影响放射控制。结论:本系统综述为成人FPA患者的放疗决策提供了循证建议。中枢神经系统指南委员会将继续寻求及时更新,以进一步改善对这种诊断的患者的护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines for the Role of Radiosurgery for Patients With Functioning Pituitary Adenomas.

Background: Patients with functioning pituitary adenomas (FPA) require a multidisciplinary team-based approach to select best medical, surgical, and radiation treatments, including stereotactic radiosurgery (SRS).

Objective: The aim of this study was to provide evidence-based recommendations on the use of SRS for adult patients with FPA.

Methods: PubMed and Embase were searched from data base inception to June 8, 2021. Full-text articles were then screened using published exclusion/inclusion criteria. Evidence tables were developing based on data extraction from the full-text reviews, and evidence-based recommendations were finalized.

Results: Of the total 1842 abstracts pertinent to this topic, 343 full articles met eligibility. Of these, 21 met entry criteria and were included in the evidence tables. The provided Class III evidence supported 2 Level III recommendations: 1. SRS, hypofractionated SRS, fractionated (>5 fractions) radiotherapy, and conventional radiation therapy provide excellent radiographic control with variable hormonal reduction and endocrine remission rates. For SRS and fractionated radiotherapy hormonal reduction may continue for up to 10 years after treatment. 2. Clinicians may continue to administer endocrine suppressive medical treatment before SRS as this may not affect radiographic control.

Conclusion: This systematic review provides evidence-based recommendations to guide providers caring for adult patients with FPA when making decisions pertinent to radiosurgery. The CNS Guidelines Committee will continue to pursue timely updates to further improve the care of patients with this diagnosis.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neurosurgery
Neurosurgery 医学-临床神经学
CiteScore
8.20
自引率
6.20%
发文量
898
审稿时长
2-4 weeks
期刊介绍: Neurosurgery, the official journal of the Congress of Neurological Surgeons, publishes research on clinical and experimental neurosurgery covering the very latest developments in science, technology, and medicine. For professionals aware of the rapid pace of developments in the field, this journal is nothing short of indispensable as the most complete window on the contemporary field of neurosurgery. Neurosurgery is the fastest-growing journal in the field, with a worldwide reputation for reliable coverage delivered with a fresh and dynamic outlook.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信